Addition of epigenetic drugs to PARPi/anti-PD1/PD-L1 is a latently synergistic strategy for potentiating immunogenic cell death and overcoming resistance due to the additional suppression of cancer stem cells in TNBC [145]. The gene discussed is PDCD1; the disease is cancer.